Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

With a trading volume of 7,459,075, the price of TEM is down by -4.37%, reaching $59.29. Current RSI values indicate that the stock is is currently neutral between overbought and oversold. Next ...

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Tempus AI, Inc. TEM recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.